Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 720 - 720

Published: March 15, 2025

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other outcomes, particularly at the cardiovascular level. Indeed, due diuretic effect, SGLT2i improve clinical chronic heart failure and reduce risk rehospitalization. In addition, reported protective effect major events mortality. More recently, it has been suggested prescription after an acute myocardial infarction may possible inflammation, arrhythmias, ventricular remodeling. Here, we reviewed focused in patients treated with percutaneous coronary intervention.

Language: Английский